However, PD‐1/PD‐L1 blockade therapy exhibits effectiveness in only a subset of patients with specific tumour types, including non‐small‐cell lung cancer, melanoma, bladder cancer, and kidney cancer.43, 44. This evidence concerns the gene PDCD1 and neoplasm.